XERS:NSD-Xeris Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 4.94

Change

0.00 (0.00)%

Market Cap

USD 0.78B

Volume

2.37M

Analyst Target

USD 11.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-31 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.05 (+0.24%)

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

-2.95 (-0.60%)

USD 65.38B
ARGX argenx NV ADR

-8.00 (-1.37%)

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

-2.32 (-0.76%)

USD 32.75B
ONC BeiGene, Ltd.

+5.79 (+2.35%)

USD 27.70B
RPRX Royalty Pharma Plc

+0.03 (+0.09%)

USD 18.35B
SMMT Summit Therapeutics PLC

+2.90 (+16.33%)

USD 13.53B
INSM Insmed Inc

+1.40 (+1.95%)

USD 11.84B
INCY Incyte Corporation

+1.80 (+2.76%)

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

-0.26 (-0.46%)

USD 11.29B

ETFs Containing XERS

BBC Virtus LifeSci Biotech Cl.. 1.62 % 0.79 %

+0.64 (+0.88%)

USD 0.01B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

+0.08 (+0.88%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 45.72% 91% A- 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 45.72% 91% A- 92% A
Trailing 12 Months  
Capital Gain 119.07% 95% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 119.07% 95% A 95% A
Trailing 5 Years  
Capital Gain -3.33% 77% C+ 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.33% 76% C+ 40% F
Average Annual (5 Year Horizon)  
Capital Gain 8.37% 62% D 64% D
Dividend Return 8.37% 62% D 61% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 60.77% 55% F 30% F
Risk Adjusted Return 13.78% 67% D+ 50% F
Market Capitalization 0.78B 81% B- 69% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.